Premier Care Network Plus - Innovation Health
APCN Choice POS II
Leomary Jiminian, MED
Counseling*
Be the first to review this provider!
Offers telehealth
Leomary Jiminian, MED
Be the first to review this provider!
North Andover, MA
Accepting new patients
Offers telehealth
Clinical Overview
Leomary Jiminian, MED works in North Andover, MA as
Offers Telehealth
This provider offers telehealth appointments. Call the office to schedule.
COMPARE OTHER TOP Counselors
Contrast Leomary Jiminian with other nearby specialists.
Candida Wiltshire, LCSW
Learn More
Joanne Beck, LPC
Learn More
Laith Gulli, LMFT
Learn More
Daphne Camille, LPC
Learn More
Tricia Park, PhD
Learn More
Anissa House, LMFT
Learn More
These providers are on the medical staff of Brightside.
Advertisement
Insurance & Payment Information
* Please verify this information when scheduling an appointment.
-
-
Blue with Managed Care Behavioral Health HMOBlue Select HMOPreferred Blue v5 PPO
-
MVP Health Plan EPO
-
Cigna PPOLocalPlusOpen Access Plus
-
HealthyBlue Advantage
-
Harvard Pilgrim Health Care HMO
-
First Health (Coventry Health Care) PPO
Office Locations
-
Richard N Warnock MD PC200 Sutton St Ste 120, North Andover, MA 01845
Patient Experience & Satisfaction
Be the first to leave a review
How likely are you to recommend Leomary Jiminian?
Step 1 of 3
Your review of Leomary Jiminian, MED
50 characters remaining
1000 characters remaining
Was this a Telehealth appointment?
(This will display with your review)
Your email is used to confirm your review and will NOT appear in the review.
This name will appear with your review. If left blank, we'll use "Anonymous".
RVO Health property, Medical News Today, is owned by RVO Health. Please review our terms of use for more.
Help other patients find the right care by sharing a few more details about your visit.
Last step! Confirm your email.
We've sent an email to
Once you confirm, you can close this window.
Thank you for your review!
Your review has been confirmed and will be published after verification.
Thank you for your review!
We've sent a confirmation email. Your review will appear after you confirm it.
Please allow up to 30 seconds for the email to arrive. Don't see it? Make sure to check your 'spam' and 'updates' folder. Once you've confirmed your review, you can close this window.
Medical Expertise & Background
Specialties*
Counseling
- *Medical News Today does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
Common Patient Questions
Leomary Jiminian, MED accepts new patients on Medical News Today.
Leomary Jiminian accepts telehealth appointments. Please call Leomary Jiminian's office to make an appointment.
Leomary Jiminian accepts Aetna, Blue Cross and Blue Shield of Massachusetts, MVP Health Care, Cigna, CareFirst BlueCross BlueShield, Harvard Pilgrim Health Care and First Health as well as many others. See all of the insurances Leomary Jiminian accepts here.
Leomary Jiminian's office is located at 200 Sutton St Ste 120 North Andover, MA 01845. Get a map and directions to Leomary Jiminian's office here.
Leomary Jiminian does not have any reviews yet.
Claim Your Profile
Are you Leomary Jiminian, MED?
Telehealth Options
This provider has not specified a telehealth appointment method. Would you still like to make an appointment with Leomary Jiminian?
Know Before You Go
Preventive care: what doctors want you to know
Preventive care can help identify current or future health and medical concerns before they become major.
Featured Stories
The FDA has approved Moderna's new mRNA flu vaccine for adults ages 50 years and older. Moderna expects the vaccine to be available in the United States for the 2026 to 2027 flu season.
A natural compound derived from plant foods containing a certain type of polyphenol may help improve heart function in people with heart failure, a study in animals and human tissue models has found.
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence in a phase 3 trial.
